Sixteen healthy, nonsmoking adult males participated in a randomized, double-blind, placebo-controlled, two-way crossover study to evaluate the influence of chronic lomefloxacin administration on the disposition of caffeine and its major metabolite, paraxanthine, at steady-state conditions. Lomefloxacin (400 mg) or placebo was administered orally once daily for 5 days to xanthine-free volunteers after an overnight fast. Caffeine (200 mg orally) was administered simultaneously with lomefloxacin on days 3 through 5. After a 2-day washout period, subjects were crossed over to the alternate 5-day regimen with caffeine, which was again given on the final 3 days. Blood samples for caffeine, paraxanthine, and lomefloxacin concentration determinations were serially collected for 48 h following the last dose of each regimen. All compounds were analyzed by high-performance liquid chromatography. For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 0.63 versus 4.07 ± 0.56 ,ug/ml), areas under the concentrationtime curve from time zero to 24 h at steady state (30.3 ± 6.9 versus 29.7 ± 6.6 ,ug h/ml), and elimination half-lives of caffeine (4.8 ± 1.1 versus 4.8 ± 1.2 h) were not significantly different. In addition, there were no significant changes in the disposition parameters of paraxanthine as a result of lomefloxacin administration. The frequencies of central nervous system-related effects for the two treatments were not statistically different. We conclude that lomefloxacin has no significant effect on the disposition of caffeine in young healthy volunteers.
Several quinolone antibiotics, including enoxacin, ciprofloxacin, and pefloxacin, have been reported to interfere with the clearance of methylxanthine compounds such as theophylline and caffeine, leading to elevated concentrations of the xanthine in serum (1, 9, 10, 17, 19, 23, 29, 33, 34) and, in the case of theophylline, central nervous system (CNS) toxicity (13, 20, 30, 32) . However, other quinolones such as norfloxacin, ofloxacin, and fleroxacin appear to have minimal or no effect on methylxanthine disposition (3, 5, 6, 9, 11, 16, 21, 25, 34) .
Lomefloxacin is an investigational difluoroquinolone that has a broad antimicrobial spectrum. Following oral administration, lomefloxacin is rapidly absorbed into the blood, widely distributed into peripheral tissues, and excreted into urine, primarily as the parent compound. It has a relatively long serum half-life (tl/2) of 6 to 8 h in volunteers with normal renal function (8) . Recent studies have shown that lomefloxacin does not significantly interfere with theophylline kinetics (12, 15, 27) . However, its effect on caffeine clearance has not been studied previously. The purpose of this study was to determine whether multiple oral doses of lomefloxacin alter the disposition of caffeine and its major metabolite, paraxanthine, at steady-state conditions in healthy volunteers.
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RESULTS
Trough concentrations of caffeine following the last two doses within each regimen were not significantly different (0.16 ± 0.17 versus 0.17 ± 0.10 ,ug/ml for caffeine-placebo and 0.16 ± 0.17 versus 0.17 ± 0.14 ,ug/ml for caffeinelomefloxacin). In addition, trough concentrations of lomefloxacin were not significantly different (0.37 0.10 ,g/ml before the fourth dose compared with 0.37 0.09 ,ug/ml before the fifth dose), indicating that steady-state conditions were achieved for both caffeine and lomefloxacin.
Multiple oral doses of lomefloxacin did not significantly alter the steady-state pharmacokinetic parameters of caffeine or paraxanthine (Table 1 and Fig. 1 and 2 of the mean) of caffeine in plasma following the last doses of the ,ug-h/ml, and 9.2 ± 2.9 versus 9.2 + 4.0 h. Differences in these parameters were not statistically significant.
All subjects completed the investigation. Although no severe adverse effects were reported, mild CNS-related complaints were documented in 8 of 16 subjects (caffeineplacebo arm of the study) and 10 of 16 subjects (caffeinelomefloxacin arm of the study) (P > 0.05). Headache (seven versus five subjects), lightheadedness (three versus three subjects), and jitteriness (two versus five subjects) occurred in subjects in the placebo and lomefloxacin-containing regimens, respectively.
DISCUSSION
Since the first published reports of CNS toxicity associated with concomitant theophylline and enoxacin administration (13, 32) , numerous investigations have been performed to assess the potential for individual quinolones to interfere with the biotransformation of methylxanthines. In vitro and clinical studies have consistently shown that enoxacin is the most potent inhibitor of xanthine metabolism, with marked reductions in theophylline and caffeine clearance of 41 to 74% and 78 to 79%, respectively (1, 9, 14, 17, 19, 26, 29, 32, 33) . Ciprofloxacin and pefloxacin are intermediate in their ability to reduce xanthine clearance (about 30% reduction for both theophylline and caffeine)., while nalidixic acid, norfloxacin, ofloxacin, and fleroxacin have little or no influence on theophylline or caffeine disposition (3, 5, 6, 9-11, 16, 21, 25, 34) .
Five studies with a total of more thati 70 healthy volunteers have demonstrated that lomefloxacin does not interfere with theophylline metabolism (12, 15, 18, 27, 31a) . Figure 3 depicts the slight structural variations between enoxacin and lomefloxacin that apparently yield differences in their abilities to inhibit xanthine N-demethylation reactions. A recent study involving human liver microsomes was performed to provide initial data on the structural requirements necessary for caffeine inhibition (5a) . They concluded that a second N atom in the quinolone nucleus leads to the most profound inhibitory effects. The resultant configuration of alternating N and C atoms structurally resembles that of theophylline and caffeine, and may therefore explain the competitive inhibition reported with enoxacin (22) . Lomefloxacin, ofloxacin, and fleroxacin lack a second N atom and are associated with minimal or no inhibition of xanthine metabolism., However, ciprofloxacin and pefloxacin also lack a second N atom in their core structures, but they demonstrate intermediate inhibitory abilities. The structural explanation(s) is multifactorial, and no single theory offered to date can fully explain (or predict) this interaction. Data from the present study indicate that multiple-dose lomefloxacin does not alter the disposition of caffeine or its primary metabolite, paraxanthine, at steady-state conditions. Mild CNS effects were common in both the caffeineplacebo group (8 of 16 subjects) and the caffeine-lomefloxacin group (10 of 16 subjects). Although headache was the most common adverse effect, the majority of subjects (five of seven in the placebo group and four of five in the lomefloxacin-containing group) registered those complaints on caffeine-free study days, suggesting that caffeine withdrawal may have been responsible (24) . In addition, the frequency of lightheadedness and jitteriness was similar between the two treatments, and all reports occurred on days when caffeine was administered.
Most studies, including the present one, have assessed potential quinolone-caffeine interactions in young healthy volunteers and have used single daily doses of caffeine of 100 to 230 mg (equivalent to 1 to 3 "cups" [180 to 540 ml] of American coffee). Since as many as 20 to 40% of coffee drinkers in the United States consume from 600 to over 1,000 mg of caffeine daily (7), further study in this population is warranted. In addition, since elderly individuals are generally thought to be more susceptible to the development of drug-induced CNS-related adverse effects (31) , they should also be studied to rule out a potentially significant pharmacodynamic interaction between quinolones and caffeine.
We conclude that lomefloxacin has no significant effect on the disposition of caffeine or on the frequency of CNSrelated adverse effects in young volunteers. Restriction of caffeine intake in this population is not necessary.
